A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

British Journal of Haematology

Volumn 143, Issue 2, 2008, Pages 201-209

  O'Connor, Owen A ^a,b   Portlock, Carol ^b   Moskowitz, Craig ^b   Straus, David ^b   Hamlin, Paul ^b   Stubblefield, Michael ^b   Dumetrescu, Otila ^b   Colevas, A Dimitrios ^c   Grant, Barbara ^d   Zelenetz, Andrew ^b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Epothilones; Indolent non Hodgkin lymphoma; Ixabepilone; Mantle cell lymphoma

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; CANCER VACCINE; CARBOPLATIN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPOTHILONE DERIVATIVE; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; IXABEPILONE; METHOTREXATE; MITOXANTRONE; PEGINTERFERON; PENTOSTATIN; PRALATREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; THALIDOMIDE; TOSITUMOMAB I 131; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; ELECTROMYOGRAPHY; EPOTHILONES; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MOTOR NEURONS; NEURAL CONDUCTION; RECURRENCE; REMISSION INDUCTION; SENSORY RECEPTOR CELLS; TREATMENT OUTCOME;

EID: 52649085233     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07271.x     Document Type: Article

References (36)

1. Abraham, J., Agrawal, M., Bakke, S., Rutt, A., Edgerly, M., Balis, F.M., Widemann, B., Davis, L., Damle, B., Sonnichsen, D., Lebwohl, D., Bates, S., Kotz, H. Fojo, T. (2003) Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. Journal of Clinical Oncology, 21, 1866 1873.
2. Ajani, J.A., Safran, H., Bokemeyer, C., Shah, M.A., Lenz, H.J., Van Cutsem, E., Burris, H.A. III., Lebwohl, D. Mullaney, B. (2006) A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Investigational New Drugs, 24, 441 446.
3. Belch, A., Kouroukis, T., Crump, M., Sehn, L., Gascoyne, R., Klasa, R., Jean, P. Eisenhaue, E. (2004) Phase II trial of bortezomib in mantle cell lymphoma. Blood, 104, Abstract 608.
4. Bollag, D.M., McQueney, P.A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz, M., Lazarides, E. Woods, C.M. (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Research, 55, 2325 2333.
5. Chabner, B.A., Bates, S.E., Fojo, A.T., Spolyar, M. Wilson, W.H. (1994) Drug resistance in adult lymphomas. Seminars in Hematology, 31, 70 87.
6. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990 4997.
7. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
8. Chou, T.C., Zhang, X.G., Balog, A., Su, D.S., Meng, D., Savin, K., Bertino, J.R. Danishefsky, S.J. (1998a) Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proceedings of the National Academy of Sciences of the United States of America, 95, 9642 9647.
9. Chou, T.C., Zhang, X.G., Harris, C.R., Kuduk, S.D., Balog, A., Savin, K.A., Bertino, J.R. Danishefsky, S.J. (1998b) Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America, 95, 15798 15802.
10. Chou, T.C., O'Connor, O.A., Tong, W.P., Guan, Y., Zhang, Z.G., Stachel, S.J., Lee, C. Danishefsky, S.J. (2001) The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proceedings of the National Academy of Sciences of the United States of America, 98, 8113 8118.
11. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867 4874.
12. Gadgeel, S.M., Wozniak, A., Boinpally, R.R., Wiegand, R., Heilbrun, L.K., Jain, V., Parchment, R., Colevas, D., Cohen, M.B. LoRusso, P.M. (2005) Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clinical Cancer Research, 11, 6233 6239.
13. Gerth, K., Bedorf, N., Hofle, G., Irschik, H. Reichenbach, H. (1996) Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. The Journal of Antibiotics, 49, 560 563.
14. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. Rodriguez, A.M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 667 675.
15. Holfe, G. (1996) Epothilones A and B novel 16-membered macrolides with cytotoxic activity: isolation, crystal structure, and confirmation in solution. Angewandte Chemie (International ed. in English), 35, 1567 1569.
16. de Jonge, M. Verweij, J. (2005) The epothilone dilemma. Journal of Clinical Oncology, 23, 9048 9050.
17. Kowalski, R.J., Giannakakou, P. Hamel, E. (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). Journal of Biological Chemistry, 272, 2534 2541.
18. Larkin, J.M. Kaye, S.B. (2006) Epothilones in the treatment of cancer. Expert Opinion on Investigational Drugs, 15, 691 702.
19. Lee, J.J. Swain, S.M. (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. Journal of Clinical Oncology, 24, 1633 1642.
20. Low, J.A., Wedam, S.B., Lee, J.J., Berman, A.W., Brufsky, A., Yang, S.X., Poruchynsky, M.S., Steinberg, S.M., Mannan, N., Fojo, T. Swain, S.M. (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. Journal of Clinical Oncology, 23, 2726 2734.
21. Mani, S., McDaid, H., Hamilton, A., Hochster, H., Cohen, M.B., Khabelle, D., Griffin, T., Lebwohl, D.E., Liebes, L., Muggia, F. Horwitz, S.B. (2004) Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clinical Cancer Research, 10, 1289 1298.
22. Meng, D.S., Balog, A., Bertinato, P., Sorensen, E.J., Danishefsky, S.J., Zheng, Y.-H., Chou, T.-C., He, L. Horwitz, S.B. (1997) Remote effects in macrolide formation through ring-forming olefin metathesis: an application to the synthesis of fully active epothilone congeners. Journal of the American Chemical Society, 119, 2733 2734.
23. Miller, T.P., Grogan, T.M., Dalton, W.S., Spier, C.M., Scheper, R.J. Salmon, S.E. (1991) P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology, 9, 17 24.
24. O'Connor, O.A. (2006) Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Current Opinion in Oncology, 18, 591 597.
25. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. Zelenetz, A.D. (2005a) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676 684.
26. O'Connor, O.A., Wright, J., Moskowitz, C., Straus, D., Portlock, C., Hamlin, P., Neylon, E., Evans, A., Winter, J., Gordon, L., Koc, O., Horvath, N., Blumel, S., Vose, J., Schenkein, D. Zelenetz, A. (2005b) Targeting the proteasome pathway with bortezomib in patients with mantle cell (MCL) and follicular lymphoma (FL) produces prolonged progression free survival amnog responding patients: results of a multicenter phase II experience. Annals of Oncology, 16, Abstract 99.
27. Rose, W.C. (1992) Taxol: a review of its preclinical in vivo antitumor activity. Anti-Cancer Drugs, 3, 311 321.
28. Rowinsky, E.K. Calvo, E. (2006) Novel agents that target tublin and related elements. Seminars in Oncology, 33, 421 435.
29. Rowinsky, E.K., Eisenhauer, E.A., Chaudhry, V., Arbuck, S.G. Donehower, R.C. (1993) Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology, 20, 1 15.
30. Sarris, A.H., Hagemeister, F., Romaguera, J., Rodriguez, M.A., McLaughlin, P., Tsimberidou, A.M., Medeiros, L.J., Samuels, B., Pate, O., Oholendt, M., Kantarjian, H., Burge, C. Cabanillas, F. (2000) Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Annals of Oncology, 11, 69 72.
31. Smith, S.M., Pro, B., van Besien, K., Conner, K., Karrison, T., Wong, S., Stiff, P. Vokes, E. (2005) A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas. Journal of Clinical Oncology, 23, Abstract ???.
32. Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P. Lister, T.A. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology, 24, 2105 2112.
33. Su, D.S. (1997) Total synthesis of (-) epothilone: an extension of the Suzuki coupling method and insigfhte into structure activity relationships of the epithlones. Angewandte Chemie (International ed. in English), 36, 757 759.
34. Thomas, E., Tabernero, J., Fornier, M., Conte, P., Fumoleau, P., Lluch, A., Vahdat, L., Bunnell, C.A., Burris, H.A., Viens, P., Baselga, J., Rivera, E., Guarneri, V., Poulart, V., Klimovsky, J., Lebwohl, D. Martin, M. (2007) Phase II clinical trial of Ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane resistant metastatic breast cancer. Journal of Clinical Oncology, 23, 3399 3406.
35. Wilson, W.H., Bryant, G., Bates, S., Fojo, A., Wittes, R.E., Steinberg, S.M., Kohler, D.R., Jaffe, E.S., Herdt, J. Cheson, B.D. (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 11, 1573 1582.
36. Zhuang, S.H., Agrawal, M., Edgerly, M., Bakke, S., Kotz, H., Thambi, P., Rutt, A., Balis, F.M., Bates, S. Fojo, T. (2005) A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer, 103, 1932 1938.